Skip to main content
SpringerLink
Log in

Mechanisms of action of intravesical bacillus Calmette-Guerin for bladder cancer

  • Chapter
Urologic Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 46))

Abstract

The use of bacteria as an immunomodulatory agent in cancer therapy was first documented in the early 1900s when Coley demonstrated tumor regression of advanced tumors with injection of microbial extracts [1]. During the 1960s, bacillus Calmette—Guerin (BCG) was noted to impart a prolonged remission in several small studies involving leukemia patients [2]. Larger cooperative studies prompted by these early successes, however, proved to be less encouraging. Throughout the early 1970s multiple studies evaluating the therapeutic effect of BCG on several tumor systems were carried out. The equivocal and somewhat disappointing results coincident with the development of new, more effective chemotherapeutic regimens resulted in a loss of initial enthusiasm.

This work was supported by USPHS Grant CA 37926-04, CA 42487-01 and CA 44426-01A1 from the National Cancer Institute.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hoodfield J: Dr. Coley’s Toxin. Science 84: 68–75, 1984.

    Google Scholar 

  2. Mathe G, Amiel JL, Schwarzenberg R, et al.: Active immunotherapy for acute lymphoblastic leukemia. Lancet 1: 697–699, 1969.

    Article  PubMed  CAS  Google Scholar 

  3. Zbar B, Rapp WJ: Immunotherapy of guinea pig with BCG. Cancer 34: 1532–1540, 1974.

    Article  PubMed  Google Scholar 

  4. Bloomberg SD, Brosman SA, Hausman MS, et al. The effect of BCG on the dog bladder. Invest Urol 12: 423–426, 1975.

    PubMed  CAS  Google Scholar 

  5. Morales A, Eidinger D, Bruce AW: Intracavitary BCG in the treatment of superficial bladder tumors. J Urol 116: 180–183, 1976.

    PubMed  CAS  Google Scholar 

  6. Camancho F, Pinsky CM, Kerr D, et al.: Treatment of superficial bladder cancer with intravesical BCG. Abstract L-160, Proc Ann Assoc, Can Res and Am Soc Clin Oncol 21: 359–360, 1980.

    Google Scholar 

  7. Lamm DL, Thor DE, Stogdill UD, et al.: Bladder Cancer Immunotherapy. J Urol 128: 931–935, 1982.

    PubMed  CAS  Google Scholar 

  8. Brosman SA: Experience with BCG in patients with superficial bladder cancer. J Urol 128: 27–30, 1982.

    PubMed  CAS  Google Scholar 

  9. Mori K, Lamm DL, Crawford DE: A trial of BCG versus Adriamycin in superficial bladder cancer: A South-West Oncology Group study. Urol Int 41: 254–259, 1986.

    Article  PubMed  CAS  Google Scholar 

  10. Morales A: Treatment of carcinoma in situ of the bladder with BCG. A phase II trial. Can Immuno Immunother 9: 69–70, 1980.

    Google Scholar 

  11. Herr HW, Pinsky CM, Whitmore WF, et al.: Long term effect of intravesical BCG or flat carcinoma-in-situ of the bladder. J Urol 135: 265–267, 1986.

    PubMed  CAS  Google Scholar 

  12. Brosman SA: The use of BCG in the therapy of bladder carcinoma in situ. J Urol 134: 36–38, 1985.

    PubMed  CAS  Google Scholar 

  13. Morales A, Nickel CJ: Immunotherapy of superficial bladder cancer with BCG. World J Urol 3: 209–214, 1986.

    Article  Google Scholar 

  14. Brendler CB, Alexander RB: Treatment of recurrent superficial transitional cell carcinoma of the bladder with intravesical bacille Calmette-Guerin (BCG). [Ab stract] J Urol Part 2 135: 284A, 1986.

    Google Scholar 

  15. Herr HW, Pinsky CM, Whitmore WF, et al.: Experience with intravesical BCG therapy of superficial bladder tumors. Urol 25: 119–123, 1985.

    Article  PubMed  CAS  Google Scholar 

  16. Lamm DL: Bacillus Calmette-Guerin immunotherapy for bladder cancer. J Urol 134: 40–47, 1985.

    PubMed  CAS  Google Scholar 

  17. Hudson MA, Ratliff TL, Gillen DP, et al.: Single course versus maintenance BCG therapy for superficial bladder tumors: A prospective randomized trial. J Urol 138: 295–298, 1987.

    PubMed  CAS  Google Scholar 

  18. Badalament, RA, Herr HW, Wang GY, Grecco C, Pinsky CM, Whitmore WF, Fair WR, Oettgen HF: A prospective randomized trial of maintenance intravesical bacille Calmette-Guerin therapy of superficial bladder cancer. J Clin Oncol 5: 441–443, 1987.

    PubMed  CAS  Google Scholar 

  19. Connolly JG: Letter to the editor. [Re: Immunotherapy of superficial bladder cancer] J Urol 130: 368, 1983.

    PubMed  CAS  Google Scholar 

  20. Lamm DL, Reichert DF, Harris SC, et al.: Immunotherapy of murine transitional cell carcinoma. J Urol 128: 1104–1108, 1982.

    PubMed  CAS  Google Scholar 

  21. Hanna MG, Zbar B, Rapp HJ: Histopathology of tumor regression after intralesional injection of Mycobacterium bovis. II. Comparative effects of vaccinia virus, oxazolone and turpentine. J Natl cancer Inst 48: 1697–1707, 1972.

    PubMed  CAS  Google Scholar 

  22. Zbar B, Bernstein ID, Rapp HJ: Suppression of tumor growth at the site of infection with living bacillus Calmette-Guerin. J Natl Cancer Inst 46(4): 831–839, 1971.

    PubMed  CAS  Google Scholar 

  23. Ratliff TL, Gillen DP, Catalona WJ: Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol 137: 155–157, 1987.

    PubMed  CAS  Google Scholar 

  24. Hakala TR, Castro A, Elliott A, et al.: Humoral cytotoxicity in human transitional cell carcinoma. J Urol 111: 382–385, 1974.

    PubMed  CAS  Google Scholar 

  25. Bubenik J, Perlman P, Helmstein K, et al.: Cellular and humoral immune responses to human urinary bladder carcinomas. Int J Cancer 5: 310–316, 1970.

    Article  PubMed  CAS  Google Scholar 

  26. Guinan P, McKiel C, Flanigan M, et al.: Cellular immunity in bladder cancer patients. J Urol 119: 747–749, 1978.

    PubMed  CAS  Google Scholar 

  27. Grossman HB: Tumor markers in urology. Semin Urol 3: 10–17, 1985.

    PubMed  CAS  Google Scholar 

  28. Soloway MS, Martino C, Hyatt C, et al.: Immunogenicity of N-[-4-(5-nitro-2-furyl)-2-thiazolyljformamide-induced bladder cancer. Natl Cancer Inst Monogr 49: 293–300, 1978.

    PubMed  Google Scholar 

  29. Morales A, Djeu J, Herberman RB: Immunization by irradiated whole cells or cell extracts against an experimental bladder tumor. Invest Urol 17(4): 310–313, 1980.

    PubMed  CAS  Google Scholar 

  30. Hellstrom I, Rollins N, Settle S, et al.: Monoclonal antibodies to two mouse bladder cancer antigens. Int J Cancer 29: 175–180, 1982.

    Article  PubMed  CAS  Google Scholar 

  31. Rook GAW: Imunologically important constituents of mycobacteria antigens. In: The Biology of the Mycobacteria, Vol. II, Ratledge C, Stanford T, (eds). Academic Press, New York, 1983, pp. 85–128.

    Google Scholar 

  32. Winters WD, Lamm DL: Antibody responses to bacillus Calmette-Guerin during immunotherapy in bladder cancer patients. Can Res 41: 2672–2676, 1981.

    CAS  Google Scholar 

  33. Minden P, McClatchy JK, Wainberg M, et al.: Shared antigens between Mycobacterium bovis (BCG) and neoplastic cells. J Natl Cancer Inst 53: 1325–1329, 1974.

    PubMed  CAS  Google Scholar 

  34. Haspel MS, McCabe RP, Pomato N, et al.: Generation of tumor cell-reactive human monoclonal antibodies using peripheral blood lymphocytes from actively immunized colorectal carcinoma patients. Cancer Res 45: 3951–3961, 1985.

    PubMed  CAS  Google Scholar 

  35. Reichert DF, Lamm DL: Long term protection in bladder cancer following intralesional immunotherapy. J Urol 132: 570–573, 1984.

    PubMed  CAS  Google Scholar 

  36. Bartlett GL, Zbar B, Rapp HJ: Suppression of murine tumor growth by immune reaction to the bacillus Calmette-Guerin strain of Mycobacterium bovis. J Natl Cancer Inst 48(1): 245–257, 1972.

    PubMed  CAS  Google Scholar 

  37. Zbar B, Bernstein ID, Bartlett GL, et al.: Immunotherapy of cancer: Regression of intradermal tumors and prevention of growth of lymph node metastases after intralesional injection of living Mycobacterium bovis. J Natl cancer Inst 49(1): 119–130, 1972.

    PubMed  CAS  Google Scholar 

  38. Kelley DR, Haaff EO, Becich M, et al.: Prognostic value of purified PPD skin test and granuloma formation in patients treated with intravesical BCG. J Urol 135: 268–270, 1986.

    PubMed  CAS  Google Scholar 

  39. Pang ASD, Morales A: Immunoprophylaxis of a murine bladder cancer with high dose BCG immunizations. J urol 127: 1006–1009

    Google Scholar 

  40. Shapiro A, Ratliff TL, Oakley DM, et al.: Reduction of bladder tumor growth in mice treated with intravesical bacillus Calmette-Guerin and its correlation with bacillus Calmette-Guerin viability and natural killer cell activity. Cancer Res 43: 1611–1613, 1983.

    PubMed  CAS  Google Scholar 

  41. Ratliff TL, Shapiro A, Catalona WJ: Inhibition of murine bladder tumor growth by bacillus Calmette-Guerin: Lack of a role of natural killer cells. Clin Immuno and Immunopath 41: 108–115, 1986.

    Article  CAS  Google Scholar 

  42. Haaff EO, Catalona WJ, Ratliff TL: Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. J Urol 136: 970–974, 1986.

    PubMed  CAS  Google Scholar 

  43. Hynes RO, Yamada KM: Fibronectins: Multifunctional modular glycoproteins. J Cell Biol 95: 369–377, 1985.

    Article  Google Scholar 

  44. Kuusela P, Vartio T, Vuento M et al.: Attachment of staphylococci and streptococci on fibronectins. Fibronectin fragments and fibrinogen bound to a solid phase. Infect Immun 50: 77–81, 1985.

    PubMed  CAS  Google Scholar 

  45. Esperson F, Clemmenson I: Isolation of a fibronectin-binding protein from Staphlococcus aureus. Infect Immunol 37: 526–531, 1982.

    Google Scholar 

  46. Simpson WA, Courtney HS, Ofek I: Interactions of fibronectin with streptococcus: The role of fibronectin as a receptor for Streptococcus pyogenes. Rev Inf Dis 9 (Suppl. 4): 5351–5359, 1987.

    Article  Google Scholar 

  47. Baughn RE: Role of fibronectin in the pathogenesis of syphilis. Rev Infec Dis 9 (Suppl. 4): 5372–5385, 1987.

    Article  Google Scholar 

  48. Calderone RA, Scheld WM: Role of fibronectin in the pathogenesis of candidal infections. Rev Infec Dis (Suppl. 4): S400–S403, 1987.

    Google Scholar 

  49. Wyler DJ: Fibronectin in parasitic diseases. Rev Infec Dis 9 (Suppl. 4): S391–S399, 1987.

    Article  CAS  Google Scholar 

  50. Keski-Ohia J, Hautanon A, Julkunen I: Fibronectin and viral pathogenesis. Rev Infect Disease 9 (Suppl. 4): S404–S411, 1987.

    Article  Google Scholar 

  51. Ratliff TL, Palmer JO, McGarr JA, et al.: Intravesical bacillus Calmette-Guerin therapy for murine bladder tumors: Initiation of the response by fibronectin-mediated attachment of bacillus Calmette-Guerin. Cancer Res 47: 1762–1766, 1987.

    PubMed  CAS  Google Scholar 

  52. Thomas WR, Schrader JW: Delayed hypersensitivity in mast-cell-deficient mice. J Immun 130: 2565–2570, 1983.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. David J. Mikkelsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy L. Ratliff
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. The Jewish Hospital of St. Louis, Washington University School of Medicine, 216 South Kingshighway Boulevard, St. Louis, Missouri, 63178, USA

    Herbert Lepor M.D.  & Timothy L. Ratliff Ph.D.  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Kluwer Academic Publishers, Boston

About this chapter

Cite this chapter

Mikkelsen, D.J., Ratliff, T.L. (1989). Mechanisms of action of intravesical bacillus Calmette-Guerin for bladder cancer. In: Lepor, H., Ratliff, T.L. (eds) Urologic Oncology. Cancer Treatment and Research, vol 46. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1595-7_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1595-7_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8883-1

  • Online ISBN: 978-1-4613-1595-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation